miCure Therapeutics
MicroRNA Therapeutics for CNS Disorders
Company Overview
Snapshot
Founded in September 2013, miCure Therapeutics operates with 1–10 employees. The company has secured $2 million across one funding round. miCure Therapeutics focuses on developing microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders, leveraging inventions from the Weizmann Institute of Science.
Business overview
miCure Therapeutics is a biotechnology company specializing in microRNA-based therapeutics and diagnostics for central nervous system (CNS) disorders. The company's core technology is based on inventions from Professor Alon Chen and Dr. Eran Hornstein of the Weizmann Institute of Science. miCure Therapeutics is developing miR-135 to address mood disorders, specifically major depression and treatment-resistant depression, by targeting gene transcripts essential for serotonergic neuronal activity. The company operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug discovery.
Company Intelligence Q&A
- What is miCure Therapeutics' primary focus?
- miCure Therapeutics is focused on developing microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders, particularly targeting central nervous system (CNS) conditions.
- What is miCure Therapeutics' lead product?
- miCure Therapeutics is developing miR-135 to treat mood disorders, including major depression and treatment-resistant depression, by targeting key gene transcripts involved in serotonergic neuronal activity.
- What is the status of miCure Therapeutics?
- miCure Therapeutics is currently non-active, having ceased operations in March 2026.
- From which institution did miCure Therapeutics' core technology originate?
- miCure Therapeutics' microRNA therapeutics and diagnostics are based on inventions by Professor Alon Chen and Dr. Eran Hornstein from the Weizmann Institute of Science.
- What is the total disclosed funding raised by miCure Therapeutics?
- miCure Therapeutics has raised a total of $2 million across one disclosed funding round.